Published online Feb 16, 2024. doi: 10.12998/wjcc.v12.i5.966
Peer-review started: November 16, 2023
First decision: December 26, 2023
Revised: December 30, 2023
Accepted: January 24, 2024
Article in press: January 24, 2024
Published online: February 16, 2024
Processing time: 75 Days and 17.6 Hours
The diagnosis of sepsis combined with acute respiratory distress syndrome (ARDS) has increased owing to the enhanced awareness among medical professionals and the continuous development of modern medical technologies, while early diagnosis of ARDS still lacks specific biomarkers. One of the main patho
To investigate the expression of PMAs in the serum of patients with sepsis complicated by ARDS and its clinical significance.
We selected 72 hospitalized patients diagnosed with sepsis as the study population between March 2019 and March 2022. Among them, 30 patients with sepsis and ARDS formed the study group, while 42 sepsis patients without ARDS comprised the control group. After diagnosis, venous blood samples were imme
The study found that the levels of PNAs and PLyAs in the serum of the study group were higher than those in the control group, but the difference was not statistically significant (P > 0.05). However, the expression of PMAs in the serum of the study group was significantly upregulated (P < 0.05) and positively correlated with the APACHE II score (r = 0.671, P < 0.05). When using PMAs as a diagnostic indicator, the area under the curve value was 0.957, indicating a high diagnostic value (P < 0.05). Furthermore, the optimal cutoff value was 8.418%, with a diagnostic sensitivity of 0.819 and specificity of 0.947.
In summary, the serum levels of PMAs significantly increase in patients with sepsis and ARDS. Therefore, serum PMAs have the potential to become a new biomarker for clinically diagnosing sepsis complicated by ARDS.
Core Tip: Our research aimed to investigate the expression of platelet mononuclear cell aggregates (PMAs) in the serum of patients with sepsis complicated by acute respiratory distress syndrome (ARDS) and its clinical significance. The results indicate that the serum levels of PMAs significantly increase in patients with sepsis and ARDS. Therefore, serum PMAs have the potential to become a new biomarker for clinically diagnosing sepsis complicated by ARDS.